

---

**From:** Borgert, Rebecca  
**Sent:** Monday, August 29, 2016 3:03 PM EDT  
**To:** Craig, Sara  
**CC:** Moore, Elboni A.  
**Subject:** FW: guidelines  
**Attachments:** Endocrine Society Guidelines 2009\_Transgender\_highlighted.pdf, image001.png, image002.jpg

Sara,

Well, it looks like Arlene beat me to the punch. This does seem to be the guideline that AHCA would want to use as a basis for criteria. I was surprised that it was so old (2009) and that it hasn't been updated but I checked the Endocrine Society website and this is the most recent version.

I highlighted the PDF I have attached in terms of things I think would be relevant to consider in the development of the criteria. I'm not sure if you've had a chance to read this or not but in a nutshell they recommend:

- Diagnosis of gender identity disorder (GID) must be made by a mental health professional and confirmed by treating endocrinologists based on the DSM-IV-TR diagnostic criteria for GID
- GnRH therapy to suppress puberty in kids that are at least Tanner stage 2. Table 5 in the document has a list of some other eligibility requirements (adequate psychosocial support, etc) that we may want to include. Definition of Tanner stages is in Table 6
- Giving estradiol or testosterone to induce opposite-sex puberty should be initiated at the age of 16 (Doses are available in Table 9)

Let me know if I can help in any other way.

Thanks,  
Becky

---

**From:** Elliott, Arlene [mailto:Arlene.Elliott@ahca.myflorida.com]  
**Sent:** Monday, August 29, 2016 2:05 PM  
**To:** Craig, Sara; Borgert, Rebecca  
**Cc:** Williams, Susan C.  
**Subject:** RE: guidelines

Summary of recommendations endocrine society:

<http://press.endocrine.org/doi/full/10.1210/jc.2009-0345>

---



Arlene Elliott - AGENCY FOR HEALTH CARE ADMINISTRATOR-SES

Bldg. 3, Rm. 2332A - BUREAU OF MEDICAID POLICY  
2727 MAHAN DR TALLAHASSEE, FL 32308  
412-4152 (Office)  
[Arlene.Elliott@ahca.myflorida.com](mailto:Arlene.Elliott@ahca.myflorida.com)



Privacy Statement: This e-mail may include confidential and/or proprietary information, and may be used only by the person or entity to which it is addressed. If the reader of this e-mail is not the intended recipient or his or her authorized agent, the reader is hereby notified that any dissemination, distribution or copying of this e-mail is prohibited. If you have received this in error, please reply to the sender and delete it immediately.

---

**From:** Elliott, Arlene  
**Sent:** Monday, August 29, 2016 1:33 PM  
**To:** Craig, Sara <[Sara.Craig@ahca.myflorida.com](mailto:Sara.Craig@ahca.myflorida.com)>; 'RJBorgert@magellanhealth.com' <[RJBorgert@magellanhealth.com](mailto:RJBorgert@magellanhealth.com)>  
**Cc:** Williams, Susan C. <[Susan.Williams@ahca.myflorida.com](mailto:Susan.Williams@ahca.myflorida.com)>  
**Subject:** guidelines

<http://transhealth.ucsf.edu/tcoe?page=guidelines-youth>



Arlene Elliott - AGENCY FOR HEALTH CARE ADMINISTRATOR-SES

Bldg. 3, Rm. 2332A - BUREAU OF MEDICAID POLICY  
2727 MAHAN DR TALLAHASSEE, FL 32308  
412-4152 (Office)  
[Arlene.Elliott@ahca.myflorida.com](mailto:Arlene.Elliott@ahca.myflorida.com)



Privacy Statement: This e-mail may include confidential and/or proprietary information, and may be used only by the person or entity to which it is addressed. If the reader of this e-mail is not the intended recipient or his or her authorized agent, the reader is hereby notified that any dissemination, distribution or copying of this e-mail is prohibited. If you have received this in error, please reply to the sender and delete it immediately.